Tislelizumab Combined With IMRT Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTT

Inclusion Criteria: * Histologically or cytologically confirmed hepatocellular carcinoma * Patients with at least one measurable lesion * Resectable primary lesion, PVTTⅡ-Ⅲtype * No previous treatment for hepatocellular carcinoma * Eastern Cooperative Oncology Group(ECOG): Performance Status(PS)score 0-1 * Child-Pugh score A * Expected survival ≥ 3 months * Baseline blood routine and blood biochemical indicators should meet the following criteria: hemoglobin ≥ 90 g/L, absolute neutrophil count ≥ 1.5 × 10 \^/L, platelet count ≥ 75 × 10 \^/L aspartate or alanine aminotransferase 5 times the upper limit of normal (ULN), alkaline phosphatase ≤ 2.5 times the ULN, serum albumin ≥ 30 g/L; serum creatinine 1.5 times the ULN; international normalized ratio (INR)) ≤ 2 or prothrombin time (PT) more than the upper limit of normal range ≤ 6 seconds * Appropriate to participate in this trial as assessed by the investigator before entering the study * Male and female subjects of childbearing potential must agree to use an effective method of contraception throughout the study * Signed informed consent. Exclusion Criteria: * Imaging showed distant metastasis * Previous treatment with other effective regimens (including surgery, radiotherapy, systemic therapy, etc.) * Previous allergic reactions to the same kind of drugs * Pregnant or lactating patients * Active hepatitis B or C (hepatitis B: HBsAg positive and Hepatitis B (HBV )DNA ≥ 1\*10\^4 IU/ml; hepatitis C: hepatitis C virus (HCV) antibody and HCV RNA positive, requiring simultaneous antiviral therapy) * Pericardial effusion, uncontrolled pleural effusion or clinically severe ascites at screening * History of interstitial lung disease, pneumonitis, or uncontrolled systemic disease, including diabetes, hypertension, pulmonary fibrosis, acute lung disease * Suffering from severe cardiovascular disease within 12 months before screening, such as symptomatic coronary heart disease,≥II congestive heart failure, uncontrolled arrhythmia, infarction, etc * Any active immunodeficiency or autoimmune disease at screening and/or any history of immunodeficiency or autoimmune disease that may recur (such as hypothyroidism or hyperthyroidism, interstitial pneumonia, enteritis, hepatitis, hypophysitis, vasculitis, myocarditis, etc.) * Use of steroids or other systemic immunosuppressive therapy 14 days before enrollment; use of steroids or other systemic immunosuppressive therapy * Patients with other previous malignancies that are not cured; Patients with other previous malignancies that are not cured * Immunocompromised patients, such as immunocompromised patients, such as human immunodeficiency virus (HIV) positive; positive * With uncontrollable psychosis; With uncontrollable psychosis * Other factors make the investigators think it is inappropriate to participate in this trial.